UNSPSC 51432310: Trimetaphan or trimethaphan

This classification denotes a nicotinic antagonist and antihypertensive agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8W556014K9. European Medicines Agency schedules Trimetaphan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11305MIG. Trimetaphan camsilate generally arises in the molecular formula C22H25N2OS.C10H15O4S. The term TRIMETAPHAN is an International Non-Proprietary Name or INN. Trimetaphan or trimethaphan bears US NLM identifiers UMLS ID C0041040 and NCI Concept Code C77369.

SMILES: C1CC2C3C(C[S+]2C1)N(C(=O)N3CC4=CC=CC=C4)CC5=CC=CC=C5.

UNSPSC 51432310 Trimetaphan or trimethaphan is a Commodity code that covers specific injectable pharmaceutical products used in emergency medical and critical-care settings. State and local governments procuring under this code buy individual medication line items—vials, injections, and other formulations—for use by fire rescue departments, emergency medical services, hospitals, and state health agencies. The actual buying under this code reflects narrow, product-specific pharmaceutical procurement: sealed bids for counted units of named drugs at firm prices, with requirements for expiration-date warranty, rapid delivery windows, Safety Data Sheets compliant with OSHA standards, and often 365-day defect warranties. Issuing bodies include city fire departments and municipal purchasing offices (as prime procurement offices), state health and human services agencies, and cooperative purchasing alliances that aggregate demand across multiple state and local jurisdictions.

Recent activity shows the code in use across Florida and Minnesota, with secondary activity in Texas. The City of Tampa's Purchasing Department issued an IFB (Solicitation 26P00188) in April 2026 for Advanced Life Support Medications to supply Tampa Fire Rescue, requesting 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials, with bids due April 8, 2026 and an estimated contract value of $40,000.00; the contract carries a one-year term with two optional one-year renewals plus three optional 30-day extensions, and includes a Small Local Business Enterprise 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (Solicitation S1070000015802) due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, including Oregon, with product availability required by May 15, 2026 and contract effectiveness July 1, 2026. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in April 2026 seeking market intelligence on direct-to-manufacturer prescription fulfillment capabilities as a precursor to formal solicitation.